Taysha gene therapies to release second quarter 2025 financial results and host conference call and webcast on august 12

Dallas, aug. 05, 2025 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system (cns), today announced that it will report its financial results for the second quarter ended june 30, 2025, and host a corporate update conference call and webcast on tuesday, august 12, 2025, at 8:30 am eastern time.
TSHA Ratings Summary
TSHA Quant Ranking